HOPE Research Institute

Welcome


HOPE Research Institute is an independent, multi-specialty, research organization dedicated to conducting clinical research trials in partnership with Valley physicians and their patients.

With NIH certified investigators and ACRP certified study coordinators, HOPE Research Institute can conduct inpatient and outpatient clinical trials across the Phoenix area.



AAHRPP Accreditation

Member of Hunt
AAHRPP

HOPE Research Institute, LLC, conducts clinical research projects for the pharmaceutical industry in the Valley of the Sun, Phoenix, Arizona. Under the careful supervision of trained, experienced physicians, Valley residents can participate in studies of investigational products. HOPE's research facility is conveniently located in North Phoenix on Union Hills Drive near the intersection of freeways 51 and 101. Participants are placed into studies in a variety of therapeutic areas, depending on their eligibility. HOPE's therapeutic ares include: Family / Internal Medicine, Gastroenterology, Neurology / Sleep Medicine, Ophthalmology, Orthopedics / Orthopedic Surgery, Pain Management, Podiatry, Urology, or Women's Health. Study participation can be a positive experience for both the physician and the patient that may provide opportunities for learning, healthcare, and the betterment of our society.

Health and Clinical Research - Latest Headlines

Food and Drug Administration--Press Releases

  • FDA and industry reach agreement in principle on medical device user fees - 01 Feb 2012The FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorization of a medical device user fee program. The recommendations would authorize the FDA to collect $595 million in user fees over five years, plus adjustments for inflation. Details of the agreement, such as the fee structure, are expected to be finalized soon.
  • FDA approves Gleevec for expanded use in patients with rare gastrointestinal cancer - 31 Jan 2012The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today?s action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the standard 12 months of treatment.
  • FDA approves Kalydeco to treat rare form of cystic fibrosis - 31 Jan 2012The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.
  • FDA takes action against New York cheese manufacturer - 31 Jan 2012The U.S. Food and Drug Administration is asking a federal court to prevent a New York cheese manufacturer from operating because of a history of unsanitary conditions and producing cheese in a facility contaminated with Listeria monocytogenes bacteria.
  • FDA approves new treatment for most common type of skin cancer - 30 Jan 2012Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic).

National Institutes of Health (NIH) News Releases

  • Gene regulator in brain's executive hub tracked across lifespan -- NIH study - 03 Feb 2012For the first time, scientists have tracked the activity, across the lifespan, of an environmentally responsive regulatory mechanism that turns genes on and off in the brain's executive hub. Among key findings of the study by National Institutes of Health scientists: genes implicated in schizophrenia and autism turn out to be members of a select club of genes in which regulatory activity peaks during an environmentally-sensitive critical period in development.
  • NIH study uncovers probable mechanism underlying resveratrol activity - 02 Feb 2012National Institutes of Health researchers and their colleagues have identified how resveratrol, a naturally occurring chemical found in red wine and other plant products, may confer its health benefits.
  • NCCAM's Advisory Council welcomes six new members - 02 Feb 2012The National Center for Complementary and Alternative Medicine (NCCAM) welcomes six new members to the National Advisory Council for Complementary and Alternative Medicine. The council serves as the principal advisory body to NCCAM, the lead federal agency for research on complementary medicine, and a component of the National Institutes of Health.
  • The NIH urges women to protect their heart health - 01 Feb 2012As part of American Heart Month, on Wednesday, Feb. 8, 2012, the National Heart, Lung, and Blood Institute's (NHLBI's) The Heart Truth campaign, with the support of the Foundation for the National Institutes of Health (FNIH), will showcase its signature event, the Red Dress Collection 2012 at Mercedes-Benz Fashion Week in New York City.

World Health Organization News

  • WHO to issue guidance on hormonal contraceptives and HIV - 03 Feb 20123 February 2012 -- Current WHO guidelines call on health service providers to remind patients, that neither hormonal contraceptives nor intrauterine devices known as IUDs offer protection against HIV or other sexually transmitted infections. Protection against both unwanted pregnancy and STIs including HIV is called "dual protection" and condoms are the mainstay of dual protection.
  • Dr Margaret Chan nominated for a second term to be WHO Director-General - 18 Jan 201218 January 2012 -- Dr Margaret Chan was nominated today by the WHOs Executive Board for a second term as Director-General of the Organization. If confirmed by the World Health Assembly, Dr Chan's new term will begin on 1 July 2012 and continue until 30 June 2017.
  • Executive Board appoints the Regional Director for the WHO Eastern Mediterranean Region - 17 Jan 201217 January 2012 -- Dr Ala Alwan will take up his appointment as the Regional Director of WHO's Eastern Mediterranean Region (WHO/EMRO) for a five-year term starting on 1 February 2012.
  • India records one year without polio cases - 11 Jan 201212 January 2012 -- India appears to have completed one year without polio since its last case on 13 January 2011. This is a momentous achievement because India was once recognized as the world?s epicentre of polio. However, there remains no room for complacency. India must maintain surveillance and high childhood immunity against wild poliovirus until eradication is achieved globally.